Corvus Pharma Com (CRVS)

$18.26 0.00 (N/A)
Market Cap 1.53B
Revenue (ttm) 0.00
Net Income (ttm) -62.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 647,300
Avg Vol 4,045,254
Day's Range N/A - N/A
Shares Out 83.77M
Stochastic %K 82%
Beta 0.73
Analysts Strong Sell
Price Target $35.00

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 900 4520
Address:
901 Gateway Boulevard, Third Floor, South San Francisco, United States
dennis59collins
dennis59collins Feb. 28 at 10:36 AM
$CRVS clinical stage updates monitored
0 · Reply
lousjamsession
lousjamsession Feb. 28 at 5:49 AM
$CRVS .....
0 · Reply
Mr_Predicto
Mr_Predicto Feb. 27 at 6:50 PM
$CRVS I must admit, today's action was easy to spot. Too many pumpers, and too much hype surrounding the "non-event" conference. I'll be looking forward to next week when we see (lack of) earnings and count how many $$$ have been thrown into the fireplace. Prediction: Continue the fade.
2 · Reply
Jellysquid1
Jellysquid1 Feb. 27 at 4:54 PM
$CRVS Here We Are Big Pharma Crvs Waiting for you! Location Below 👇👇
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 4:10 PM
$CRVS Current Stock Price: $18.57 Contracts to trade: $19.0 CRVS Mar 20 2026 Call Entry: $1.25 Exit: $1.63 ROI: 30% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:39 PM
$CRVS lots of unhappy shorts I bet?
0 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:28 PM
$CRVS We’re on the run now! Just a matter of time. Best in class new MOA!!
0 · Reply
tradingjunk321
tradingjunk321 Feb. 27 at 3:13 PM
$CRVS Some nice posts today!
1 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:12 PM
$CRVS let’s roll!!
0 · Reply
Gaia2
Gaia2 Feb. 27 at 3:11 PM
$CRVS Shall we start a Go Fund Me page for all the re-tard shorts? I'll start by pledging a quarter! Anyone for a dime?
1 · Reply
Latest News on CRVS
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 4:01 PM EST - 4 days ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 23, 2026, 5:00 PM EST - 5 weeks ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 10:53 PM EST - 5 weeks ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Jan 21, 2026, 2:50 PM EST - 5 weeks ago

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Jan 21, 2026, 11:43 AM EST - 5 weeks ago

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Jan 20, 2026, 5:15 PM EST - 5 weeks ago

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 4:01 PM EST - 5 weeks ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:10 PM EST - 5 weeks ago

What made Corvus stock double on Tuesday and is it sustainable?

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 20, 2026, 2:00 PM EST - 5 weeks ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 16, 2026, 4:01 PM EST - 6 weeks ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:16 PM EST - 4 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 4 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 31, 2025, 7:30 AM EDT - 4 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 28, 2025, 4:01 PM EDT - 4 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 17, 2025, 10:00 AM EDT - 4 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Oct 2, 2025, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 12, 2025, 11:31 PM EDT - 7 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:20 PM EDT - 7 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jun 4, 2025, 7:00 AM EDT - 9 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 9, 2025, 11:57 AM EDT - 10 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:06 PM EDT - 10 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:02 PM EDT - 10 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 8, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 23, 2025, 4:08 PM EDT - 11 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Apr 9, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:30 AM EDT - 1 year ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 28, 2025, 9:29 AM EDT - 1 year ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 7:58 PM EDT - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:36 PM EST - 1 year ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

dennis59collins
dennis59collins Feb. 28 at 10:36 AM
$CRVS clinical stage updates monitored
0 · Reply
lousjamsession
lousjamsession Feb. 28 at 5:49 AM
$CRVS .....
0 · Reply
Mr_Predicto
Mr_Predicto Feb. 27 at 6:50 PM
$CRVS I must admit, today's action was easy to spot. Too many pumpers, and too much hype surrounding the "non-event" conference. I'll be looking forward to next week when we see (lack of) earnings and count how many $$$ have been thrown into the fireplace. Prediction: Continue the fade.
2 · Reply
Jellysquid1
Jellysquid1 Feb. 27 at 4:54 PM
$CRVS Here We Are Big Pharma Crvs Waiting for you! Location Below 👇👇
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 4:10 PM
$CRVS Current Stock Price: $18.57 Contracts to trade: $19.0 CRVS Mar 20 2026 Call Entry: $1.25 Exit: $1.63 ROI: 30% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:39 PM
$CRVS lots of unhappy shorts I bet?
0 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:28 PM
$CRVS We’re on the run now! Just a matter of time. Best in class new MOA!!
0 · Reply
tradingjunk321
tradingjunk321 Feb. 27 at 3:13 PM
$CRVS Some nice posts today!
1 · Reply
dwsrph1
dwsrph1 Feb. 27 at 3:12 PM
$CRVS let’s roll!!
0 · Reply
Gaia2
Gaia2 Feb. 27 at 3:11 PM
$CRVS Shall we start a Go Fund Me page for all the re-tard shorts? I'll start by pledging a quarter! Anyone for a dime?
1 · Reply
tradingjunk321
tradingjunk321 Feb. 27 at 1:21 PM
$CRVS Revolutionary Drug coming! Much much Moore to come! EASI 92 and easy $92 😂
1 · Reply
lousjamsession
lousjamsession Feb. 27 at 5:58 AM
$CRVS ....
0 · Reply
Gaia2
Gaia2 Feb. 26 at 10:42 PM
$CRVS Steady as she goes! Full speed ahead!
1 · Reply
KingKai2020
KingKai2020 Feb. 26 at 8:55 PM
$CRVS the Oppenheimer analysts made one comment late that I have disussed over the past year.... his congratualations about validating the ITK platform. Clearly the shorts do not appreciate the significance, but they will soon enough.
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 26 at 8:55 PM
$CRVS WOW!
1 · Reply
abc12332
abc12332 Feb. 26 at 8:53 PM
$CRVS Good presentation. As I expected nothing new. Just repeating the great results up to this point. They gave a new 2026 milestone slide. Something is obviously missing. I don’t get it. intentionally ignoring a study is generally a negative indicator. They really cooled on mentioning Cifo prior to the negative data release. On the other hand, Miller would have to be virtually lying for ALPS data to be anything but good after his BioTV interview comments. I’m just confused why they are intentionally burying it since the interim data are like now.
6 · Reply
Mr_Predicto
Mr_Predicto Feb. 26 at 8:21 PM
$CRVS I hope everyone enjoyed the conference. I know I did. Let's recap: Any new partnerships? Nope New trial results/updates? Sorry Exciting news to report? Umm, no Prediction - Crystal ball please tell me if there was anything concrete offered to shareholders?
1 · Reply
VISIUM
VISIUM Feb. 26 at 7:38 PM
$CRVS What company name does everyone use to login to these webcasts? I use RT Inc.
0 · Reply
fubar444
fubar444 Feb. 26 at 5:15 PM
$CRVS Oppenheimer call starts at 2:40pm today! https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-present-oppenheimer-36th-annual
2 · Reply
Semiraz
Semiraz Feb. 26 at 3:49 PM
$CRVS are we about to fall down another 20% 😎
1 · Reply
dwsrph1
dwsrph1 Feb. 26 at 2:34 PM
$CRVS feel like it’s about to rain!😂😂😁
0 · Reply
KingKai2020
KingKai2020 Feb. 26 at 2:17 PM
$CRVS https://www.fiercebiotech.com/biotech/boehringer-pens-500m-pact-british-biotech-oral-approach-autoimmune-diseases partnerships will be coming and with far better terms.
0 · Reply